Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
Open Access
- 20 February 2004
- Vol. 100 (7) , 1449-1458
- https://doi.org/10.1002/cncr.20132
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemiaCancer Chemotherapy and Pharmacology, 2002
- Acute Myeloid LeukemiaHematology-American Society Hematology Education Program, 2002
- Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute LeukemiaLeukemia & Lymphoma, 2000
- Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaJournal of Clinical Oncology, 1999
- Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemiaAnnals of Oncology, 1999
- Activity of Oral and Intravenous 9-Aminocamptothecin in SCID Mice Engrafted with Human LeukemiaLeukemia & Lymphoma, 1998
- Results of Topotecan Single-Agent Therapy in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaLeukemia & Lymphoma, 1998
- Water Soluble Inhibitors of Topoisomerase I: Quaternary Salt Derivatives of CamptothecinJournal of Medicinal Chemistry, 1996
- Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase IJournal of Medicinal Chemistry, 1995
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemiaBlood, 1993